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Introduction: Short-course external beam radiotherapy
(EBRT) and intraluminal brachytherapy are both accepted
treatments for the palliation of dysphagia in patients with
incurable esophageal cancer. We compared the effects of
both treatments from two prospective studies.
Methods: We performed a multicenter prospective cohort
study of patients with metastasized or otherwise incur-
able esophageal cancer requiring palliation of dysphagia
from September 2016 to March 2019. Patients were
treated with EBRT in five fractions of 4 Gy. Data were
compared with all patients treated with a single brachy-
therapy dose of 12 Gy in the SIREC (Stent or Intraluminal
Radiotherapy for inoperable Esophageal Cancer) trial,
both between the original cohorts and between 1:1 pro-
pensity score–matched cohorts. The primary end point
was an improvement of dysphagia at 3 months without
reintervention. The secondary end points included toxicity
and time-to-effect.
Results: A total of 115 patients treated with EBRT and 93
patients who underwent brachytherapy were eligible foranalysis. In the original cohorts, dysphagia improved after
EBRT in 79% of patients compared with 64% after
brachytherapy (p ¼ 0.058). Propensity score matching
resulted in 69 patients in each cohort well-balanced at
baseline. Improvement of dysphagia was observed in 83%
after EBRT versus 64% after brachytherapy (p ¼ 0.048). In
responding patients, improvement of dysphagia at 2 weeks
was observed in 67% after EBRT compared with 35% after
brachytherapy, and the maximum effect was reached after 4
weeks in 55% and 33%, respectively. Severe toxicityJournal of Thoracic Oncology Vol. 15 No. 8: 1361–8
1362 Jeene et al Journal of Thoracic Oncology Vol. 15 No. 8occurred in 3% of patients after EBRT compared with 13%
after brachytherapy.
Conclusions: Short-course EBRT appears at least as effec-
tive as brachytherapy in the palliation of dysphagia in pa-
tients with esophageal cancer.
 2020 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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Annually, approximately 572,000 patients are diag-
nosed with esophageal cancer worldwide.1 In the
Netherlands, the overall 5-year survival is approximately
22%.2 The poor prognosis is mainly the result of a high
incidence of distant metastasis at the time of diagnosis.
For incurable patients, palliation of symptoms is the key
to maintaining an acceptable quality of life. The pre-
dominant debilitating symptom of an advanced esopha-
geal tumor is dysphagia, with 80% to 90% of all patients
experiencing difficulties with swallowing at some point
during their clinical course.3,4 With a median life ex-
pectancy between 4 and 10 months in these patients,
palliative treatment should be short, rapidly effective,
and minimally invasive.5-7
Different types of treatment are available for
dysphagia relief, including stenting, laser therapy,
external beam radiotherapy (EBRT), and intraluminal
brachytherapy. Determining the optimal strategy for
treating dysphagia remains a challenge, mainly owing
to a lack of evidence regarding one modality over the
other.8 In the SIREC trial (Stent or Intraluminal
Radiotherapy for inoperable Esophageal Cancer), pa-
tients were randomized between a single dose of 12
Gy brachytherapy and self-expanding metal stent
placement.9 Although the effect of brachytherapy was
longer-lasting, patients who received a stent experi-
enced a quicker relief in dysphagia; thus, the latter
should be reserved for patients with very short life
expectancy. Furthermore, a recent meta-analysis
revealed that single-dose brachytherapy was superior
to fractionated brachytherapy in terms of the onset of
toxicity; although fractionated brachytherapy led to a
higher cumulative dose and yielded improved
dysphagia-free survival rates.10 Given the results of
these studies (among others), the European Society of
Gastrointestinal Endoscopy and Dutch guidelines
recommend stent placement for patients with a life
expectancy of fewer than 3 months.11,12 For patientswith a relatively longer life expectancy, single-dose
brachytherapy is recommended.
Despite these guidelines, a recent study revealed a
wide variation in palliative treatment modalities in the
Netherlands, with EBRT being used far more frequently
than brachytherapy.11,13 The authors stated that
although clinical decision-making is largely based on
patient-related and disease-related characteristics, it is
also associated with the hospital of diagnosis.
Given the generally poor survival of these patients,
treatment needs to be widely available and rapidly
effective, with the burden of toxicity being minimal.
Furthermore, the duration of the palliative effect should
be long in relation to their prognosis. Therefore, a
shortcourse EBRT should be preferred over a more frac-
tionated course. The literature on the use of EBRT in the
palliative setting is scarce. A few retrospective series
reveal fairly good results with a wide range of radio-
therapy schedules.14,15 To date, no prospective data exists
that evaluated the efficacy of short-course EBRT in the
palliation of dysphagia. There is a surplus of evidence on
the use of brachytherapy compared with the use of EBRT,
yet EBRT is applied more often. Hence, a randomized
study comparing both modalities would be desirable.
However, owing to the paucity of the actual use of
brachytherapy, a randomized trial between brachyther-
apy and EBRT is no longer considered feasible.
Therefore, we performed a multicenter prospective
registration trial to investigate the effectiveness of EBRT
in five fractions of 4 Gy. Inclusion criteria and end points
were similar to those of the SIREC study, enabling a
direct comparison with the original data from the
brachytherapy results of the SIREC trial. We hypothe-
sized that EBRT would be at least as effective as
brachytherapy for palliation of dysphagia caused by
incurable esophageal cancer.
Materials and Methods
We performed a nationwide, multicenter, prospective
cohort study of patients with metastasized or otherwise
incurable esophageal cancer requiring palliation of
dysphagia (Netherlands Trial register NL7198). All pa-
tients were treatedwith EBRT in five fractions of 4 Gy. This
cohort was compared with the patients in the SIREC trial
whowere treatedwith single-dose brachytherapy of 12 Gy.
Details of the SIREC trial were reported previously.9 The
study was approved by the Medical Ethics Review Com-
mittee of the AcademicMedical Center and the Institutional
Review Boards of all participating centers. All participating
patients provided written informed consent.
Study Population
Inclusion criteria were based on the inclusion of the
SIREC study. Eligible for inclusion were patients with
August 2020 Short-Course EBRT vs. Brachytherapy in Dysphagia 1363metastatic esophageal cancer or patients who were no
longer candidates for curative locoregional treatment
and were being referred for radiotherapy to relieve
dysphagia.
Dysphagia grade greater than or equal to 2 according
to the Ogilvie scale was mandatory before the start of
EBRT.16 Histologic confirmation of a squamous cell car-
cinoma, adenocarcinoma, or large-cell undifferentiated
carcinoma of the esophagus or esophagogastric junction
was required. A computed tomography (CT) of the chest
and abdomen not more than 3 months old had to be
available. The maximum tumor length was set at 12 cm,
and the extension into the cardia of the stomach had to
be less than 5 cm. Exclusion criteria were the presence of
an esophageal stent, (suspicion of) tumor growth into
the tracheal lumen, a life expectancy of fewer than 3
months, previous esophagectomy, previous radiotherapy
to the mediastinum to a radiobiologic equivalent dose of
greater than 20 Gy, and chemotherapy administered
from 1 week before EBRT to 1 week after radiotherapy.Radiotherapy
EBRT was given with a dosage of 20 Gy in five frac-
tions of 4 Gy. Radiation was delivered using a linear
accelerator with a photon energy of 6 to 18 MV. The
gross tumor volume (GTV) consisted of the primary tu-
mor plus the direct adjacent pathologic lymph nodes that
could be (partly) responsible for the obstructive effect.
No elective volume was delineated. The clinical target
volume (CTV) was defined as the GTV plus 1 cm in
craniocaudal direction and 0.5 cm in a lateral and ante-
roposterior direction. If organs at risk were not involved
in the tumor process, they were excluded from the CTV.
The planning target volume (PTV) was CTV plus 1 cm in
all directions. In the case of online cone-beam CT-veri-
fication, a reduction in CTV-PTV margin was allowed on
the basis of local practice. The radiation therapy
required at least a three-dimensional planning tech-
nique. The prescription dose was defined according to
the International Commission on Radiation Units and
Measurements 83 criteria.17 If lung tissue was over-
lapping with the PTV, an 85% isodose coverage in that
area was accepted. Brachytherapy was prescribed as a
single dose of 12 Gy at 1 cm from the source axis of the
applicator. The standard active length of the application
was the tumor length plus 2 cm extra at both ends of the
tumor.9Outcome Measures
The primary end point was an improvement of
dysphagia score at 3 months without reintervention ac-
cording to the Ogilvie score by greater than or equal to
one point.16 Dysphagia was scored as follows: score 0,ability to eat a normal diet; score 1, ability to eat some
solid food; score 2, ability to eat some semisolids only;
score 3, ability to swallow liquids only; and score 4,
complete obstruction.
The secondary end points were time to maximum
effect, duration of dysphagia relief, and overall survival
(OS). The first improvement of dysphagia and time to the
maximum effect was assessed at 2 weeks, 1 month, 2
months, and 3 months after treatment. Subgroup ana-
lyses were performed for the effectiveness of EBRT on
the basis of histology or baseline dysphagia score. Sur-
vival was calculated from the first day of radiotherapy
until death. Toxicity greater than or equal to grade 3
according to Common Terminology Criteria for Adverse
Event version 4.0 was scored for each patient. The pro-
gression of dysphagia for which reintervention was
indicated was considered as treatment failure.Follow-Up
Baseline characteristics, including dysphagia scores,
were retrieved before the start of the study. In the EBRT
cohort, patients received a diary in which they scored
dysphagia every week until the first 8 weeks after
treatment. Diaries were retrieved by the investigators
after 3 months. Follow-up was mandatory at 3, 6, 9, and
12 months after treatment. Follow-up by telephone was
permitted if a hospital visit was no longer possible. In
the brachytherapy cohort, patients were prospectively
followed up by home visits by one of six specially trained
research nurses at 14 days, 1 month, and then monthly
until 1 year after treatment. Patients received a diary in
which they scored dysphagia every day for 1 month and
every week thereafter. Toxicity and reinterventions were
scored at each visit. A reintervention for dysphagia was
considered as a study end point, after which no further
dysphagia was registered.Statistical Analysis
In univariable analyses, we used the chi-square test
and t test to assess baseline and outcome differences
between patient groups in categorical and continuous
data, respectively. Survival was calculated from the date
of the first radiotherapy to the date of death or last
follow-up, plotted using Kaplan-Meier curves and
compared using a log-rank test.
We used propensity score matching to adjust for
imbalances in baseline characteristics between the two
groups. A propensity score was generated using logistic
regression on the basis of the covariates age, sex, WHO
performance score greater than or equal to 2, previous
chemotherapy, tumor characteristics (histology, tumor
location, and tumor length), and reason for palliation
(i.e., metastasized or inoperable esophageal cancer).
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replacement (1:1) was performed to generate matched
pairs of cases in which the within-pair difference was
minimized by setting a caliper of 0.1 of the SD of the logit
of the propensity score.
The primary and secondary outcomes were
compared both between the original (nonmatched) co-
horts and between the propensity score–matched
cohorts.
A two-tailed p value of less than 0.05 was considered
significant in all statistical analyses. SPSS version 25.0
(IBM Corp, IBM SPSS Statistics for Windows, Armonk,
NY) was used for study analyses.
Results
A total of 124 patients were included in the EBRT
group. Data were compared with all 101 patients ran-
domized to brachytherapy in the SIREC trial (Fig. 1). At
the time of analyses, all patients treated with brachy-
therapy, and 95 of patients treated with EBRT had died.
A minimum follow-up of 5 months was available for all
patients.Figure 1. Study profile. EBRT, external beam radiotherapy;
Esophageal Cancer.Patient- and tumor-related characteristics were
comparable between the two groups (Table 1). Mean
tumor length was larger in the brachytherapy cohort
than the EBRT cohort (7.4 versus 5.9 cm, respectively, p
< 0.001). In the brachytherapy group, 14% of patients
had involvement of the esophagogastric junction versus
34% in the EBRT group (p ¼ 0.001). WHO performance
status was generally higher in the brachytherapy group
than in the EBRT group. However, WHO performance
status greater than or equal to 2 was comparable with
29% versus 31%, respectively (p ¼ 0.73). After pro-
pensity score matching, 138 patients (69 in each group)
were selected for comparative analyses. No significant
differences in baseline characteristics remained.
Improvement in Dysphagia Score
In the original cohorts, 55 patients (59%) in the
brachytherapy group were available for analyses of the
primary end point at 3 months and 67 patients (58%) in
the EBRT group (Fig. 1). Improvement in dysphagia by
greater than or equal to one point after 3 months
occurred in 35 patients (64%) after brachytherapy andSIREC, Stent or Intraluminal Radiotherapy for inoperable
Table 1. Baseline Characteristics of Original Cohorts and After Propensity Score Matching
Original Cohorts Matched Cohorts
Brachytherapy
(n ¼ 93)
EBRT
(n ¼ 115) p Value
Brachytherapy
(n ¼ 69)
EBRT
(n ¼ 69) p Value
Age, y (mean ± SD) 69 (12) 72 (9) 0.038 70 (13) 70 (9) 0.84
Male sex, n (%) 69 (74) 91 (79) 0.40 50 (73) 52 (75) 0.70
Tumor type, n (%) 0.10 0.75
Adenocarcinoma 63 (68) 91 (80) 47 (68) 51 (74)
Squamous cell carcinoma 27 (29) 22 (19) 21 (30) 17 (25)
Other 3 (3) 1 (1) 1 (1) 1 (1)
Tumor length, cm (mean ± SD) 7.4 (2.5) 5.9 (2.7) <0.001a 6.8 (2.5) 6.5 (2.5) 0.46
Tumor location, n (%) 0.001a 0.83
Esophagus 80 (86) 76 (66) 56 (81) 57 (83)
Esophagogastric junction 13 (14) 39 (34) 13 (19) 12 (17)
Reason for palliative treatment, n (%) 0.09 0.37
Metastases 72 (77) 97 (87) 55 (80) 59 (86)
Inoperable 21 (23) 15 (13) 14 (20) 10 (14)
Previous chemotherapy, n (%) 11 (12) 8 (7) 0.26 7 (10) 6 (9) 0.81
WHO performance, n (%) <0.001a 0.038a
0 31 (34) 16 (15) 21(30) 12 (17)
1 34 (37) 58 (54) 28(41) 38 (55)
2 16 (18) 30 (28) 12(17) 17 (25)
3 10 (11) 3 (3) 8(12) 2 (3)
WHO performance WHO, n (%) 0.73 0.85
0–1 65 (71) 74 (69) 49 (71) 50 (72)
2 26 (29) 33 (31) 20 (29) 19 (28)
Dysphagia score before treatment, n (%) 0.36 0.14
2 38 (41) 56 (49) 26 (38) 36 (52)
3 36 (39) 42 (37) 28 (40) 25 (36)
4 19 (20) 16 (14) 15 (22) 8 (12)
Dysphagia score at 3 mo available, n (%) 55 (59) 67 (58) 0.99 39 (57) 42 (61) 0.73
aStatistically significant.
EBRT, external beam radiotherapy.
August 2020 Short-Course EBRT vs. Brachytherapy in Dysphagia 1365in 53 patients (79%) after EBRT (p ¼ 0.058). In the
matched cohorts, 39 patients (57%) in the brachyther-
apy group were available for analyses of the primary end
point at 3 months and 42 patients (61%) in the EBRT
group (p ¼ 0.73). Improvement of dysphagia greater
than or equal to one point after 3 months occurred
significantly more frequently in the EBRT group than the
brachytherapy group (83% versus 64%, respectively;
p ¼ 0.048).
In the original cohorts, time to the improvement of at
least one point and time to maximum effect was signif-
icantly shorter after EBRT than brachytherapy. In the
patients treated with EBRT, the first improvement of
dysphagia was observed after 2 weeks in 67% compared
with 36% after brachytherapy, and 87% versus 60%,
respectively at 4 weeks (p ¼ 0.01, Fig. 2). More than half
of patients (55%) with an improvement of dysphagia
reached their maximum effect within 4 weeks after
EBRT compared with 33% after brachytherapy (p ¼
0.021, Fig. 3).Duration of Effect
Persistent improvement of dysphagia was analyzed
in the original cohorts. At 6 months after treatment,
persistent improvement of dysphagia was present in 27
of 38 surviving patients in the brachytherapy group
compared with 18 of 28 surviving patients in the EBRT
group (p ¼ 0.56). At 9 months after treatment, these
numbers were 16 of 22 versus 10 of 13 patients,
respectively (p ¼ 0.78).Survival
On comparison of the original cohorts, median OS
was 5.1 months in the brachytherapy group (95% con-
fidence interval [CI]: 3.9–6.3 mo) and 4.4 months in the
EBRT group (95% CI: 2.8–6.0 mo, p ¼ 0.8) (Fig. 4).
After matching, OS was 4.8 months in the
brachytherapy group (95% CI: 3.2–6.5 mo) and
5.3 months in the EBRT group (95% CI: 3.1–7.5 mo,
p ¼ 0.25).
36%
67%
24%
20%
17%
9%
24%
4%
Brachytherapy EBRT
3 months
2 months
1 month
2 weeks
Time to first improvement
Figure 2. Time to improvement of dysphagia by at least one
point after treatment. Results are revealed in percentages
for patients with improvement of dysphagia and available
data at 3 months after treatment. EBRT, external beam
radiotherapy. 0 3 6 9 12
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Figure 4. Overall survival according to treatment group.
EBRT, external beam radiotherapy.
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In the original cohorts, similar reintervention rates
for dysphagia were observed between the brachytherapy
and EBRT groups (28% versus 25%, p ¼ 0.61). Median
time to reintervention was 3.2 months in the brachy-
therapy group (95% CI: 0.5–5.9 mo) compared with 3.7
months (95% CI: 2.5–5.0 mo) in the EBRT group (p ¼
0.78), and after matching, 3.2 months (95% CI: 0.23–6.1
mo) versus 4.6 months (95% CI: 1.7–7.4 mo), respec-
tively (p ¼ 0.26). Reinterventions after brachytherapy
included stent placement (73%), repeated brachyther-
apy (12%), or removal of food impaction (12%). AfterFigure 3. Time to maximum improvement of dysphagia after
treatment. Results are revealed in percentages for patients
with improvement of dysphagia and available data at 3
months after treatment. EBRT, external beam radiotherapy.EBRT, reinterventions included stent placement (54%)
or repeated EBRT (35%).
Toxicity
In the original cohorts, grade greater than or equal to
3 toxicity after EBRT occurred in 3% of patients. At 3
months, one patient (1%) experienced grade 3 pneu-
monia, one patient (1%) experienced grade 3 radiation-
induced esophagitis, and one patient (1%) developed a
fistula 5 months after treatment. One patient (1%) had
grade 3 gastrointestinal toxicity 6 months after treat-
ment but was also treated with systemic therapy at that
time. Grade greater than or equal to 3 toxicity occurred
in 13% of patients after brachytherapy, as reported
previously.9
Subgroup Receiving EBRT
In the original cohort of patients treated with EBRT,
we determined the effect of histology. For patients with
adenocarcinoma, improvement of dysphagia of greater
than or equal to one point after 3 months occurred in
82%, whereas for patients with a squamous cell carci-
noma, 64% (p ¼ 0.30). When patients were analyzed in
subgroups on the basis of dysphagia score before treat-
ment, response rates were 74%, 89%, and 83% for pa-
tients with dysphagia scores 2, 3, and 4, respectively
(p ¼ 0.43).
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Dysphagia is the most frequent symptom in patients
with metastasized or otherwise incurable esophageal
cancer. We compared the effect of EBRT and brachy-
therapy for improvement of dysphagia greater than or
equal to one point at 3 months. Brachytherapy was
effective in 64% of patients compared with 79% after
EBRT (p ¼ 0.058). After propensity score matching,
improvement of dysphagia occurred in 64% after
brachytherapy and in 83% patients after EBRT (p ¼
0.048). Dysphagia also improved more rapidly after
EBRT than after brachytherapy. Thus, short-course EBRT
appears at least as effective as brachytherapy in the
palliation of dysphagia in patients with esophageal
cancer.
The likelihood of improvement of dysphagia after
EBRT was not dependent on the severity of dysphagia at
presentation. More specifically, patients with a
dysphagia score of 4 (complete obstruction) had similar
effects compared with patients with a lower dysphagia
score before treatment. This in contrast to patients
treated with brachytherapy, in whom an initial
dysphagia score of 4 was prognostically unfavorable, as
reported previously.18 However, as numbers are very
small for these subgroups, no definitive conclusions
should be drawn other than the finding that EBRT seems
to be also indicated in this subgroup. We found no dif-
ference in effect between adenocarcinoma and squa-
mous cell carcinoma, suggesting that histology should
not influence the choice for EBRT.
Reported toxicity in brachytherapy was higher than
the EBRT group. In the SIREC trial, grade greater than or
equal to 3 complications were observed in 13%.9 A
recent meta-analysis found severe adverse events in
23% of treated patients, mostly including
brachytherapy-related stenosis (12%) and fistula for-
mation (8%).10 The higher reported toxicity in the
brachytherapy series might be explained by the much
higher dose at the esophageal mucosa. The biologically
equivalent dose at the reference point is fairly similar
between five times 4 Gy and a single dose of 12 Gy.19,20
However, the dose distribution in brachytherapy is very
inhomogeneous. A dose of nearly 200% of the prescribed
dose is delivered at the surface of the esophageal wall,
dropping to 100% at 5 mm into the esophageal wall, and
to less than 50% at 20 mm. Thus, a tumor with a
thickness of more than 1 cm will be underdosed in the
deeper parts. As this is a fundamental aspect of intra-
luminal brachytherapy more modern brachytherapy
techniques using advanced image guidance cannot
compensate for this effect. In contrast, EBRT has a very
homogeneous dose distribution over the GTV, with the
target volume received between 95% and 107% of theprescribed dose.17 We speculate that the superior effect
of EBRT can well be explained by a better dose coverage
of the entire tumor compared to brachytherapy. The
higher dose in the mucosa when using brachytherapy
might also be a cause of more edema resulting in pro-
longed dysphagia.
In our study, a short-course EBRT regimen was
chosen to minimize the patient burden. Murray et al.15
retrospectively analyzed 148 patients who had been
treated with palliative radiotherapy for esophageal can-
cer, mostly with five fractions of 4 Gy. Most patients had
dysphagia (93%). Response was defined as any degree of
patient-reported improvement of dysphagia at 4 to 6
weeks after completion of radiotherapy or thereafter. In
line with our results, they found an improvement of
dysphagia in 75% of patients, and toxicities were mild
with a total grade 3 toxicity rate of only 3%. No grade 4
or 5 toxicities were seen. A recent retrospective study
investigated the effect of EBRT up to total doses of 20,
30, or 39 Gy. The authors observed improvement of
symptoms in 72% of patients without differences be-
tween radiotherapy schedules.14 A phase I–II study from
2008, using 40 Gy in 20 fractions with two fractions per
day, reported a response rate of 69% in dysphagia relief
with a median response duration of 5.5 months.21Similar
results were found by others after 30 to 35 Gy in 10 to
15 fractions.22,23 Taken together, a short-course of EBRT
seems equally effective as a more protracted course and
is, therefore, preferable.
Logistics for EBRT are generally more convenient
than for brachytherapy. EBRT can be applied at every
normally equipped radiation department, whereas
brachytherapy requires special equipment and treat-
ment rooms, and also educated personnel for proper
monitoring of the patient in case of mild sedation. The
procedure requires the presence of a gastroenterologist,
a radiation oncologist, an imaging technician, and staff
for anesthesia and endoscopy assistance all at the same
time. These logistics can be challenging, often causing a
delay in the start of treatment. In contrast, EBRT re-
quires a planning-CT scan and five brief (10 min) time-
slots on a linear accelerator, does not require the
presence of a radiation oncologist, and is regular treat-
ment at a radiation oncology department. However,
EBRT requires five visits to the clinic, whereas brachy-
therapy can be administered in only 1 day.
The main strengths of our study are the following: (1)
the prospective multicenter design of both compared
studies, (2) the treatment being uniform within each
treatment group, and (3) the similar inclusion criteria for
both treatment groups. Patients treated with brachy-
therapy were treated 15 years before those treated with
EBRT; hence, we cannot exclude the possibility that this
affected the results. However, OS was similar between
1368 Jeene et al Journal of Thoracic Oncology Vol. 15 No. 8groups and, in general, has not substantially improved in
this period for these patients.2 To compensate for possible
differences, propensity score matching was performed to
further create comparable groups. However, it is not a
randomized study, and the effects of differences in diag-
nosis, staging, and treatment have undeniably evolved
over the past 15 years. Therefore, bias through potential
unknown confounders cannot be excluded.
Conclusions
On the basis of this matched analysis of two prospective
studies, short-course EBRT appears at least as effective as
brachytherapy in the palliation of dysphagia in esophageal
cancer. Dysphagia improved more often and more rapidly
after EBRT than after brachytherapy. Considering the
limited toxicity and advantages in logistics, EBRT should be
the preferred treatment for the relief of dysphagia. This is
true for both adenocarcinoma and squamous cell carcinoma,
and also for all grades of dysphagia.
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